BMRN


BioMarin Gets EMA Permit for Accelerated Assessment of Valoctocogene Roxaparvovec

BioMarin Pharmaceutical Inc. (BMRN), a global biotechnology company received the European Medicines Agency (EMA) approval for accelerated assessment of valoctocogene roxaparvovec.

BioMarin Reports Better-Than-Expected 1Q Results

Biotechnology company BioMarin Pharmaceutical (BMRN) posted 1Q results that beat analysts’ estimates. Revenue decreased 3.

BioMarin Tanks 36% As FDA Rejects Hemophilia A Gene Therapy Application

Shares in BioMarin Pharmaceutical plunged 36% after the US Food and Drug Administration (FDA) in a surprise move rejected the biotech company’s license …

BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A

Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy …

3 Healthcare Stocks That Are Coming Back to Life

After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign …

3 Best Stocks for 2020: The Race Is On

2020 just kicked off, but investors aren’t wasting any time. Rolling up their sleeves and getting straight down to business, they know the …

These 3 “Strong Buy” Healthcare Stocks Have 40% Upside — Or More, Says Cowen

The world’s population is getting older, rapidly. According to the United Nations, the fastest-growing age group across the world is adults aged 65 …

Are These 5 Biotech Stocks About to Get Bought Out?

In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …

Company Update (NASDAQ:BMRN): BioMarin Pharmaceutical Inc. Announces Public Offering of Common Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten …

Oppenheimer Shines Light on BioMarin Pharmaceutical Inc. (BMRN) Following FDA Advisory Meeting for Kyndrisa

Oppenheimer analyst Christopher Marai came out today with a few insights on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), after attending the FDA advisory meeting for Kyndrisa, the company’s treatment for Duchenne …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts